The absence of a standardized definition for graft-versus-host disease (GVHD) flares and data on its clinical course are significant concerns. We retrospectively evaluated 968 patients across 23 Mount Sinai Acute GVHD International Consortium (MAGIC) transplant centers who achieved complete response (CR) or very good partial response (VGPR) within 4 weeks of treatment. The cumulative incidence of flares within 6 months was 22%, and flares were associated with a higher risk of nonrelapse mortality (NRM; adjusted hazard ratio [aHR], 4.84; 95% confidence interval [CI], 3.19-7.36; P < .001) and had more frequent lower gastrointestinal (LGI) involvement (55% vs 32%; P
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Akahoshi, Y., Spyrou, N., Hoepting, M., Aguayo-Hiraldo, P., Ayuk, F., Chanswangphuwana, C., … Nakamura, R. (2024). Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis. Blood Advances, 8(8), 2047–2057. https://doi.org/10.1182/bloodadvances.2023012091